RHBDF1 and neoplasm: The superior antitumor activity of the combination therapy is likely attributed to several mechanisms including the direct growth inhibiting activity of iRhom1 KD, the increased sensitivity of tumor cells to chemotherapy agents, and activated antitumor immune response.